Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)

医学 来曲唑 肿瘤科 内科学 浆液性液体 临床终点 妇科 临床研究阶段 临床试验 不利影响 疾病 安全概况 外科 随机对照试验 进行性疾病 总体生存率 完全响应 打开标签 疾病控制
作者
Brian M. Slomovitz,S. John Weroha,Wei Deng,Hye Sook Chon,Vivek Podder,Merry Jennifer Markham,Floor Backes,Eric D. Thomas,Lee-may Chen,Meaghan Tenney,Shannon N. Westin,Merry Jennifer Markham,David S. Miller,Mitchell I. Edelson,Carolyn Y. Muller,Michael J. Callahan,Laura L. Holman,J. Rebecca Liu,Eleonora Teplinsky,Aparna A. Kamat
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (3): 153-163 被引量:7
标识
DOI:10.1200/jco-25-01348
摘要

PURPOSE: Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)-p16-Rb pathway, features shared with hormone receptor-positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS: This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION: Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小于发布了新的文献求助10
1秒前
科目三的应助被fff采纳,获得10
1秒前
sasa发布了新的文献求助20
1秒前
1秒前
彭于晏的应助被Tyl采纳,获得10
2秒前
younger发布了新的文献求助10
2秒前
3秒前
haha完成签到 ,获得积分10
3秒前
3秒前
4秒前
4秒前
4秒前
5秒前
3921337477发布了新的文献求助10
5秒前
6秒前
6秒前
人间枝头发布了新的文献求助10
6秒前
Linzi发布了新的文献求助10
7秒前
zombie发布了新的文献求助10
7秒前
3921337477发布了新的文献求助10
8秒前
9秒前
rrl发布了新的文献求助10
9秒前
10秒前
xiaozhang发布了新的文献求助10
10秒前
Jackpu完成签到,获得积分10
10秒前
10秒前
3921337477发布了新的文献求助10
12秒前
12秒前
Lucas的应助被小卢采纳,获得10
12秒前
Linzi完成签到,获得积分10
13秒前
吴大振完成签到,获得积分10
13秒前
然目之绮发布了新的文献求助10
13秒前
祝诗蕍发布了新的文献求助10
13秒前
上官若男的应助被叉叉采纳,获得30
14秒前
飘逸的山柏完成签到,获得积分10
14秒前
14秒前
qin202569发布了新的文献求助30
15秒前
16秒前
air-yi完成签到,获得积分0
17秒前
思源的应助被带着星星旅行采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184508
求助须知:如何正确求助?哪些是违规求助? 9573478
关于积分的说明 21831914
捐赠科研通 7781737
什么是DOI,文献DOI怎么找? 3434372
关于科研通互助平台的介绍 2558482
邀请新用户注册赠送积分活动 2480962